Last reviewed · How we verify
Alnovin — Competitive Intelligence Brief
phase 2
fendosal
Plasminogen activator inhibitor 1
Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Alnovin (FENDOSAL). Alnovin works by inhibiting the activity of Plasminogen activator inhibitor 1 (PAI-1), a protein that helps regulate blood clot formation.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Alnovin TARGET | FENDOSAL | phase 2 | fendosal | Plasminogen activator inhibitor 1 | ||
| Retaane | anecortave | marketed | anecortave | Plasminogen activator inhibitor 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (fendosal class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Alnovin CI watch — RSS
- Alnovin CI watch — Atom
- Alnovin CI watch — JSON
- Alnovin alone — RSS
- Whole fendosal class — RSS
Cite this brief
Drug Landscape (2026). Alnovin — Competitive Intelligence Brief. https://druglandscape.com/ci/fendosal. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing